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Background Advances in high-throughput genomics facilitate the identification of novel genetic susceptibility variants for
coronary heart disease (CHD). This may improve CHD risk prediction. The aim of the present simulation study was to investigate
to what degree CHD risk can be predicted by testing multiple genetic variants (genetic profiling).
Methods We simulated genetic profiles for a population of 100,000 individuals with a 10-year CHD incidence of 10%.
For each combination of model parameters (number of variants, genotype frequency and odds ratio [OR]), we calculated the
area under the receiver operating characteristic curve (AUC) to indicate the discrimination between individuals who will and will
not develop CHD.
Results The AUC of genetic profiles could rise to 0.90 when 100 hypothetical variants with ORs of 1.5 and genotype
frequencies of 50% were simulated. The AUC of a genetic profile consisting of 10 established variants, with ORs ranging from
1.13 to 1.42, was 0.59. When 2, 5, and 10 times as many identical variants would be identified, the AUCs were 0.63, 0.69,
and 0.76.
Conclusion To obtain AUCs similar to those of conventional CHD risk predictors, a considerable number of additional
common genetic variants need to be identified with preferably strong effects. (Am Heart J 2009;158:105-10.)The genetics of coronary heart disease (CHD) has
received great interest over the last decades with the latest
developments in high-throughput genomics and genome-
wide association studies.1-4 Not only will these advances
lead to better understanding of the etiology of CHD, it is
also expected that genetic profiling, that is, the simulta-
neous testing of multiple genetic variants, can eventually
be used to predict CHD risk in individuals. This may lead
to personalized medicine in which preventive and
therapeutic interventions will be targeted at genetic
profiles rather than at conventional risk factors. A
potential advantage of genetic profiling above conven-
tional risk factors in the prediction of CHD risk is that
genetic information is already present at birth. Therefore,
genetic profiles could theoretically predict CHD risk
before conventional risk factors become apparent. The
expectations are high,5-7 but the question remains
whether genetic profiling will indeed become useful for
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doi:10.1016/j.ahj.2009.04.022A recent study investigated the combined influence on
CHD risk of a genetic profile consisting of 10 genetic
variants that were all significantly associated with CHD in
published meta-analyses.5 In a simulation study, the
authors determined the expected frequency of individuals
with different numbers of risk genotypes and their effect
on CHD risk. Although this study showed that individuals
with a high number of risk genotypes had a very high
CHD risk compared with individuals with a low number
of risk genotypes, the authors did not investigate whether
this genetic profile discriminated between individuals
who will develop CHD and those who will not.
Discriminative accuracy is the first requirement for a
valuable predictive test and can be expressed as the area
under the receiver operating characteristic curve (AUC).8
Previous studies that investigated the discriminative
accuracy for prediction of CHD generally found small
discriminative accuracies of genetic profiles (AUC in the
order of 0.60, denoting little discrimination).9,10 Whereas
these previous studies only considered genetic profiles
consisting of a limited number of genetic variants, most
likely, a much larger number of genetic variants with
small effects is involved in CHD.11 Inclusion of more
genetic variants in genetic profiles may further improve
their discriminative accuracy.
The aim of the present study was to investigate what we
can expect from genetic profiling in the prediction of CHD
with the currently known genetic variants and when more
genetic variants associated with CHD will be identified in
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genetic profiles with that of CHD prediction models based
on conventional risk factors. Because limited empirical
data are available of large-scale genetic profiling, simulation
studies were required for the present analyses.Methods
Modeling strategy
We used a modeling procedure that created a dataset with
information on genetic profiles and disease status for a
population of 100,000 individuals. We simulated genetic profiles
that consisted of multiple genetic variants, which can be
polymorphisms or haplotypes.
The modeling procedure has been published in detail else-
where11 but is briefly as follows: For the construction of the
genetic profiles, we assumed (1) that each genetic variant only
had a risk variant and a wild-type variant, therefore, interpretable
as a dominant or recessive mode of inheritance, (2) that genetic
variants inherited independently, that is, no linkage disequili-
brium existed between the genetic variants, and (3) that the
combined effect of the genetic variants on disease risk followed a
multiplicative risk model of independent genetic effects, that is,
no statistical interaction terms were included in the model.12,13
The modeling was done in 3 steps: (1) modeling the genetic
profiles of all individuals, (2) calculating the cumulative 10-year
CHD risks associated with the genetic profiles, and (3) modeling
the CHD status of all individuals. We constructed the genetic
profiles by randomly assigning the genotypes of each genetic
variant to all individuals in the population, so that the genotype
distributions are in line with the specified genotype frequencies.
The CHD risks associatedwith the genetic profileswere calculated
using Bayes theorem. Bayes theorem states that the posterior odds
of CHD for each individual are obtained by multiplying the prior
odds by the likelihood ratio (LR) of their test result. The prior odds
are calculated from the baseline population CHD risk (p) using the
formula p/(1 − p). The LR of the test result refers to the LR of the
genetic profile,14 which, under the assumption of independent
genetic effects, was obtained by multiplying the LRs of all
individual genotypes that constitute the profile. The LRs of the
genotypes of the single genetic variants were calculated from a
2-by-2 contingency table presenting genotype by disease status.
This table is constructed from the genotype frequency, the
population CHD risk, and the strength of association between the
risk genotype of a genetic variant and CHD risk, quantified by
the odds ratio (OR). These are all specified as parameters that
vary between different simulation scenarios (see below). The
posterior odds are converted into CHD risks using the formula
odds/(1 + odds). Finally, to model CHD status, we used a
simulation procedure that assigns disease status to individuals
based on the CHD risks associated with their genetic profiles. This
procedure ensures that for individuals with the same disease risk,
the percentage of individuals who will develop CHD equals that
CHD risk, when the subgroup of individuals with that CHD risk
would have been sufficiently large.11
Discriminative accuracy
The discriminative accuracy is the extent to which test results
can discriminate between individuals who will develop CHD and
those who will not.8,15 The AUC is commonly used to quantifythe discriminative accuracy of a prediction model.16 The AUC is
the probability that the test correctly identifies the diseased
individual from a pair of whom one is affected and one is
unaffected and ranges from 0.5 (total lack of discrimination) to
1.0 (perfect discrimination).17 The AUC was obtained as the
c-statistic by the R function somers2, which is available in the
Hmisc library of R software.18 Simulation studies can simulate
any number of genes with any strength of effect. Yet, the
contribution of genetic factors in the development of CHD is
bounded, as indicated by the heritability. In each scenario, we
calculated the proportion of explained variance (R2) as a proxy
measure of the heritability, that is, the total contribution of
genetic factors in the specific scenario.11 All simulations were
repeated 10 times to obtain robust estimates of the AUC and
proportion of explained variance; all results are presented as
averages of the repeated simulations. Analyses were performed
using R software (version 2.5.1).18
Simulation scenarios
We considered 3 different scenarios, in each of which we
simulated genetic profiles and CHD status for 100,000 indivi-
duals, and a 10-year cumulative CHD risk of 10%.
First, to gain a first impression of the discriminative accuracy
of genetic profiles, we simulated genetic profiles consisting of
50 and 100 genetic variants that all had the same OR and
genotype frequency. For each genetic profile, we obtained the
distribution of the number of risk genotypes in the population.
Subsequently, we investigated the AUCs of the genetic profiles.
In separate simulations, we considered different combinations
of ORs (1.1, 1.2, and 1.5) and genotype frequencies (10%, 30%,
and 50%).
Second, we considered genetic profiles defined by 10
established genetic variants of which the combined effect on
CHD risk was recently studied.5 We constructed genetic profiles
consisting of genetic variants that had ORs and genotype
frequencies identical to the 10 established genetic variants. We
calculated the AUC of simultaneously testing these 10 variants,
and additionally, we estimated the expected AUC when 2, 5, and
10 times as many genetic variants with the same distribution of
ORs and genotype frequencies would be known, that is, genetic
profiles consisting of 20, 50, and 100 genetic variants in total.
Finally, we investigated conditions in which genetic profiling
yields a similar discriminative accuracy as conventional CHD risk
prediction scores. We hereto compared the AUC of genetic
profiles with that of the Framingham and PROCAM risk
scores.19,20 The AUCs of these scores were between 0.75 and
0.82 in the original studies,20,21 but subsequent studies have
reported AUCs of 0.61 to 0.68 in European populations.22,23 For
different genotype frequencies, we investigated the magnitude of
the ORs of 1 to 100 additional genetic variants needed to obtain
an AUC of 0.65, 0.70, or 0.75 in a panel already consisting of the
10 genetic variants described in the second scenario.
No extramural funding was used to support this work. The
authors are solely responsible for the design and conduct of this
study, all study analyses, the drafting and editing of the article,
and its final contents.
Results
Genetic profiling of 50 genetic variants with genotype
frequencies of 10%, 30%, and 50% resulted in a mean
Table I. Discriminative accuracy as a function of the OR and risk
genotype frequency
OR Genotype
frequency⁎
AUC 50
genes
R2 AUC
100 genes
R2
1.1 10% 0.56 0.5% 0.59 1.0%
30% 0.59 1.1% 0.63 2.1%
50% 0.61 1.5% 0.64 2.6%
1.2 10% 0.62 1.9% 0.66 3.8%
30% 0.68 4.7% 0.74 8.3%
50% 0.69 4.7% 0.75 9.1%
1.5 10% 0.75 10% 0.82 19%
30% 0.83 20% 0.89 32%
50% 0.84 21% 0.90 33%
All genes involved in the genetic profiles have the same ORs and risk genotype
frequencies. R2, proportion of explained variance by genetic variants.
⁎Risk genotype frequency.
Table II. Established genetic variants from published meta-
analyses
Gene, variant Risk
genotype
OR Risk genotype
frequency
ACE, insertion/deletion intron 16 D/D 1.22 28%
APOB, Q4154K K+ 1.32 27%
APOE, E2/E3/E4 E4+ 1.42 23%
CETP, Taq1b B1+ 1.24 68%
ITGA2B, P1(A2) A2+ 1.13 27%
LPL, S447X S/S 1.25 80%
MTHFR, C677T T/T 1.14 12%
NOS3, E298D D/D 1.31 11%
PON1, Q192R R192+ 1.15 21%
SERPINE1, 5G/4G 4G/4G 1.20 31%
Data obtained from Drenos et al.5
Figure 1
Distributions of the genetic profiles. Distributions of the genetic profiles
in simulated populations as a function of the risk genotype frequency
(upper panel 10%, middle panel 30%, and lower panel 50%). Genetic
profiles were defined by 50 (left panel) or 100 genetic variants
(right panel). All genes involved in the genetic profiles had the same
ORs and risk genotype frequencies. The x-axis indicates the number of
risk genotypes of 50 or 100 genetic variants in the genetic profiles.
The y-axis indicates the percentage of individuals in the simulated
population, for example, 18% of the population carries 4 risk
genotypes when the genotype frequency is 10% and the genetic
profile consists of 50 genetic variants.
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Volume 158, Number 1number of risk genotypes in the simulated population of
5, 15, and 25, respectively (Figure 1). The observed
range of the number of risk genotypes was 0 to 13 when
the genotype frequency was 10% and 14 to 36 when the
genotype frequency was 50%. These numbers were
more or less doubled for genetic profiles consisting of
100 genetic variants. As expected, higher genotype
frequencies, higher ORs, and larger numbers of genetic
variants yielded a higher discriminative accuracy (Table
I). The AUC of genetic profiles ranged from 0.56 when
50 genetic variants with ORs of 1.1 and genotype
frequencies of 10% were simulated to 0.90 when 100
genetic variants with ORs of 1.5 and genotype
frequencies of 50% were simulated (Table I). Similarly,
the proportion of explained variance ranged from 0.5%
to 33% (Table I).The discriminative accuracy was 0.59 for a genetic
profile based on the 10 genetic variants that were
significantly associated with CHD in published meta-
analyses (Table II). When 2, 5, and 10 times as many
genetic variants with the same distribution of ORs and
genotype frequencies would be identified, the expected
AUCs were 0.63, 0.69, and 0.76, respectively.
Table III shows the magnitude of the ORs and genotype
frequencies of genetic variants that are needed in addition
to the original genetic profile of 10 genetic variants to
obtain AUCs similar to that of the conventional CHD risk
prediction scores. For instance, an AUC of 0.75 could be
obtained when 10 additional genetic variants would be
identified that have an OR of at least 1.8, depending on the
genotype frequency. For 20, 50, or 100 additional genetic
variants, the minimal ORs were 1.5, 1.3, and 1.2,
depending on the genotype frequency (Table III).
Discussion
An important factor in the potential success of genetic
profiling in the prediction of CHD is the discovery of
Table III. Minimal ORs needed to obtain AUCs comparable with
that of the Framingham and PROCAM risk scores in addition to the
10 genetic variants (AUC = 0.59) in Table II
Risk genotype
frequency
No. of additional
genetic variants
AUC
0.65
AUC
0.70
AUC
0.75
0.05 1 3.9 7.3 13.6
5 2.1 2.8 3.8
10 1.7 2.1 2.7
20 1.5 1.8 2.2
50 1.3 1.5 1.7
100 1.2 1.3 1.5
0.10 1 2.8 4.8 7.5
5 1.8 2.3 2.8
10 1.5 1.9 2.2
20 1.4 1.6 1.8
50 1.2 1.4 1.5
100 1.1 1.2 1.3
0.30 1 2.2 3.3 5.0
5 1.5 1.8 2.2
10 1.4 1.6 1.8
20 1.3 1.4 1.5
50 1.2 1.3 1.3
100 1.1 1.1 1.2
0.50 1 2.2 3.5 6.7
5 1.4 1.8 2.2
10 1.3 1.5 1.8
20 1.2 1.4 1.5
50 1.1 1.2 1.3
100 1.1 1.1 1.2
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with CHD. We have shown that genetic profiling based
on 10 established genetic variants yielded a lower
discriminative accuracy for the prediction of CHD
(AUC 0.59) than the PROCAM and Framingham risk
prediction scores that are commonly used in general
populations to guide medical decisions about who
should receive risk-reducing medication.19,20 The AUCs
of these conventional risk prediction scores were
originally reported to be between 0.75 and 0.8220,21
but lower in subsequent studies (AUCs ranging between
0.61 and 0.68).22,23 To obtain AUCs similar to those of
the original studies, a considerable number of additional
common genetic variants with high ORs needs to be
identified. This may prove difficult because the genetic
variants with the highest ORs may already have been
discovered, which means that even a higher number of
genetic variants with small ORs is needed. We are aware
that the more extreme scenarios presented in this study
might not be realistic and consider our simulated series
of 100 genetic variants with ORs of 1.5 and a frequency
of 50% each as an upper bound of the plausible range of
genetic effects.
The discriminative accuracy that is required in pre-
ventive or clinical care depends on the goal of testing, the
burden of disease, the availability of (preventive) treat-
ment, and the adverse effects of false-positive and false-negative test results. For instance, the identification of
individuals at increased CHD risk will result in prescrip-
tion of medication that partly reduces this CHD risk and
has a low risk of adverse effects. Here, a small proportion
of false positives and/or false negatives is acceptable.
Therefore, an AUC between 0.70 and 0.80 would, in this
example, indicate moderate performance, whereas an
AUC above 0.80 would denote good performance. In
contrast, the AUCs needed for decisions about invasive
and irreversible interventions or for presymptomatic
diagnosis are much higher.
A valuable predictive test should not only have an
appreciable AUC but should also be well calibrated.
Calibration reflects the level to which the observed
probabilities equal the predicted probabilities but is not
indicative of the degree to which a test discriminates
between individuals who will and will not develop CHD.
In other words, a well-calibrated prediction model could
show low discrimination. Nevertheless, the calibration
was 100% in our simulations because of the way we
assigned disease status to the individuals. Recently, the
value of the AUC as a measure of the discriminative
accuracy has been questioned.24 Critics claim that
researchers should not solely rely on the change in
AUC to evaluate the value of risk factors for the
prediction of complex diseases but propose to determine
the extent of reclassification in clinically important risk
categories.24 Despite the fact that individuals might be
reclassified into different risk categories with consequent
changes in treatment decisions, the question remains if
this reclassification is accurate and correct. We believe,
however, that reclassification could be useful in choosing
the “best” prediction model when the AUCs of these
models are comparable.
An advantage of genetic profiling in predicting CHD
risk could be that its information can be used at a
younger age before the conventional risk factors, such as
hyperlipidemia, hypertension, and diabetes mellitus,
become apparent. This could potentially increase the
opportunities for prevention of CHD because damaging
effects of long-term exposure to conventional risk factors
can be prevented. For instance, young individuals who
have an adverse genetic profile may adopt a healthier
lifestyle. It is, however, not known how likely lifestyle
changes will be made and maintained throughout life. An
alternative scenario is that genetic profiling may improve
the prediction of CHD over and above that of conven-
tional risk factors. In the present simulations, we did not
take these conventional risk factors into account, but
because of the modeling strategy, our results can be
interpreted as combinations of nongenetic and genetic
risk factors. Several empirical studies in CHD and other
complex diseases have demonstrated limited added
predictive value so far.9,10,25,26 This could be due to the
fact that most genetic association studies have focused
on genetic variants related to conventional risk factors
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have additional predictive value, if the conventional risk
factors are already present in the prediction model.27 In a
previous study on CHD risk, a cardiovascular risk score
based on conventional risk factors yielded an AUC of
0.76 in whites.10 The AUC improved to 0.77 by adding 11
genetic risk factors to the prediction model.10 Such a
small improvement, whereas statistically significant, is
most likely not clinically relevant.
Our simulation study showed that genetic profiling of
50 or 100 genetic variants could result in higher AUCs
compared with the conventional prediction models. Yet,
calculation of the proportion of explained variance, as a
proxy of the heritability, indicates that some of these
scenarios might not be realistic. Twin studies have
shown that the heritability of CHD death is in the order
of 40%.28 With a proportion of explained variance of
33%, the AUC was 0.90. Higher proportions of explained
variance, yielding higher AUCs, might not be possible for
CHD. AUCs higher than 0.90 can only be expected if all
genetic variants underlying CHD risk would be identi-
fied, including very infrequent genetic variants with very
small effects. This may be practically impossible, even
with consortia of considerable size. For example,
detecting ORs of 1.05, 1.02, or 1.01, whereas 1% of
the population has the genetic variant, and with 80%
power, requires sample sizes more than 1.3, 8.1, or 32
million individuals.
In conclusion, we have shown that the degree to
which genetic profiling is able to predict CHD risk is
limited but can be improved by using a large number of
common genetic variants with relatively high ORs. To
date, we are not able to achieve discriminative
accuracies similar to the current CHD risk prediction
tools based on the currently known genetic suscept-
ibility variants for CHD. With the latest developments in
genomewide association studies, it is expected that the
knowledge about genetic risk factors for CHD will
expand.2,29 However, the fact that only one locus
identified in the latest genomewide association studies
has been successfully replicated is not very promising.30
The question therefore remains whether the number of
additional genetic variants, together with their ORs and
genotype frequencies, will be high enough to substan-
tially influence the discriminative accuracy for CHD
risk prediction.References
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